PRESS RELEASE published on 01/15/2025 at 07:30, 1 year 9 months ago Inside Information / Other news releases GenSight Biologics announces the publication of 5-year outcomes for patients treated with LUMEVOQ® gene therapy, showing sustained bilateral improvement in visual acuity and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity Safety Profile
BRIEF published on 01/13/2025 at 11:31, 1 year 9 months ago Heights Capital Management dépasse 5% du capital de GenSight Biologics Augmentation De Capital GenSight Biologics Actions Et Droits De Vote Heights Capital Management Participation Capital
BRIEF published on 01/13/2025 at 11:31, 1 year 9 months ago Heights Capital Management exceeds 5% stake in GenSight Biologics Capital Increase Shares And Voting Rights GenSight Biologics Heights Capital Management Capital Participation
PRESS RELEASE published on 01/13/2025 at 11:26, 1 year 9 months ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management, Inc. pour Gensight Biologics S.A. avec détention de 7 574 746 actions et 9,62% des droits de vote Déclaration Actions Franchissement De Seuils Gensight Biologics S.A. Heights Capital Management Inc.
BRIEF published on 12/24/2024 at 20:51, 1 year 10 months ago GenSight Biologics Secures €1.5 Million Financing from Existing Investors Investors Warrants Financing Gene Therapy GenSight Biologics
BRIEF published on 12/24/2024 at 20:51, 1 year 10 months ago GenSight Biologics obtient un financement de 1,5 million d'euros auprès d'investisseurs existants Financement Investisseurs Thérapie Génique Mandats GenSight Biologics
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 10 months ago Inside Information / Other news releases GenSight Biologics announces a c. €1.5 million financing from existing investors through a Reserved Offering to support gene therapy development for retinal diseases and CNS disorders Financing Gene Therapy GenSight Biologics Retinal Diseases Reserved Offering
PRESS RELEASE published on 12/24/2024 at 20:46, 1 year 10 months ago Informations privilégiées / Autres communiqués GenSight Biologics annonce un financement de 1,5 million d'euros auprès d'investisseurs existants pour le développement de thérapies géniques innovantes. Perspectives de croissance et objectifs à court terme Croissance Financement Investisseurs GenSight Biologics Thérapies Géniques
BRIEF published on 11/13/2024 at 07:35, 1 year 11 months ago GenSight Biologics Submits LUMEVOQ® Dossier to ANSM Gene Therapy GenSight Biologics Early Access Program Leber Hereditary Optic Neuropathy Regulatory Submission
BRIEF published on 11/13/2024 at 07:35, 1 year 11 months ago GenSight Biologics dépose le dossier LUMEVOQ® auprès de l'ANSM Thérapie Génique GenSight Biologics Programme D'accès Anticipé Neuropathie Optique Héréditaire De Leber Soumission Réglementaire
Published on 10/28/2026 at 22:35, 6 hours 56 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 17 hours 1 minute ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 17 hours 1 minute ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 17 hours 1 minute ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 17 hours 1 minute ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/29/2026 at 00:15, 5 hours 15 minutes ago Infinite Electronics Showcases Engineered Connectivity Solutions at electronica 2026
Published on 10/28/2026 at 21:35, 7 hours 55 minutes ago Food & Beverage Manufacturers Race to Scale AI Beyond the Pilot Stage
Published on 10/28/2026 at 21:15, 8 hours 16 minutes ago Amrize Completes $1 Billion Share Repurchase Program
Published on 10/28/2026 at 20:36, 8 hours 54 minutes ago Vonovia’s Core Business Remains Resilient as Higher Financing Costs and Weaker Transaction Business Shape 2027 Guidance and 2028 Objectives
Published on 10/28/2026 at 17:56, 11 hours 34 minutes ago OPR - Mise à disposition de l'addendum au rapport d'expertise indépendante
Published on 10/28/2026 at 17:45, 11 hours 46 minutes ago VOGO obtains FIBA (International Basketball Federation) Approval for its Instant Replay System.
Published on 10/28/2026 at 17:45, 11 hours 46 minutes ago Successful issue of a € 6.0 billion bond as part of the financing of the PTC acquisition
